Protagonist Therapeutics (PTGX) Shares Outstanding (2015 - 2026)

Protagonist Therapeutics has reported Shares Outstanding (Entity) for 12 years, with the latest figure at $64.2 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 3.71% year-over-year to $64.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $64.2 million (up 3.71% YoY) and the FY2025 annual result came in at $62.6 million, up 2.53% from the prior year.
• Shares Outstanding (Entity) rose to $64.2 million in Q1 2026 per PTGX's latest filing, from $62.6 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $64.2 million in Q1 2026 and troughed at $48.6 million in Q1 2022.
• A 5-year average of $57.1 million and a median of $58.6 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Entity) rose 18.1% in 2023, then gained 2.21% in 2024.
• Over 5 years, Shares Outstanding (Entity) stood at $49.3 million in 2022, then climbed by 16.96% to $57.7 million in 2023, then increased by 5.76% to $61.0 million in 2024, then grew by 2.53% to $62.6 million in 2025, then gained by 2.64% to $64.2 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $64.2 million, $62.6 million, and $62.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.